MOTS-c: Dosing Protocols

Research Dosing Disclaimer#

MOTS-c is not approved for human use by any regulatory agency. No human dosing protocols have been established through clinical trials. The information below is derived exclusively from preclinical animal studies and is provided for educational and research context only. No human dosing recommendations can or should be inferred from animal data without proper clinical development, including Phase 1 dose-finding studies in humans.

Preclinical Dosing Data#

All published dosing data for MOTS-c come from mouse studies. The primary dose used across the key preclinical publications is 5 mg/kg body weight administered by intraperitoneal (IP) injection. This dose has been used consistently across multiple research groups and experimental paradigms.

Lee et al. 2015 - Discovery Study (Cell Metabolism)#

The original study that characterized MOTS-c as an exercise mimetic used the following protocol in C57BL/6 mice:

• Dose: 5 mg/kg body weight
• Route: Intraperitoneal injection
• Frequency: Daily
• Duration: Variable across experimental arms
• Context: High-fat diet-fed mice; evaluated prevention of obesity and insulin resistance
• Outcome: MOTS-c-treated mice on high-fat diet showed significantly reduced body weight gain, improved glucose tolerance, and enhanced insulin sensitivity compared to vehicle controls

Kim et al. 2018 - Nuclear Translocation Study (Cell Metabolism)#

Studies examining MOTS-c's nuclear translocation under metabolic stress used:

• Dose: 5 mg/kg body weight
• Route: Intraperitoneal injection
• Context: Glucose restriction and oxidative stress models
• Key finding: Demonstrated that MOTS-c translocates to the nucleus within hours of stress exposure, regulating antioxidant response element (ARE)-containing genes

Reynolds et al. 2021 - Aging Study#

Studies in aged mice used MOTS-c to evaluate physical performance and metabolic restoration:

• Dose: 5 mg/kg body weight
• Route: Intraperitoneal injection
• Subjects: Aged mice (equivalent to approximately 65 human years)
• Outcome: Improved treadmill running capacity, restored metabolic parameters toward youthful levels, enhanced skeletal muscle function

Dosing Summary Table#

Route of Administration#

All published preclinical studies with exogenous MOTS-c have used intraperitoneal (IP) injection in mice. This route provides direct access to the peritoneal cavity with rapid systemic absorption and is standard for mouse pharmacology studies, but it is not a route commonly used in human therapeutics.

No published data exist for:

• Subcutaneous injection of MOTS-c
• Intravenous administration of MOTS-c
• Oral administration of MOTS-c
• Any other route of administration

The feasibility and bioavailability of MOTS-c by alternative routes remain unknown. As a 16-amino acid peptide without known special stability features, MOTS-c would be expected to undergo rapid proteolytic degradation if administered orally, and its bioavailability by subcutaneous injection would need to be empirically determined.

Human-Equivalent Dose Considerations#

No human dosing has been established for MOTS-c. Allometric scaling from mouse to human is frequently employed as a preliminary step in dose estimation, but it carries significant limitations and should not be used to derive clinical dosing without formal Phase 1 studies.

Using the standard FDA body surface area (BSA) scaling method (mouse Km = 3, human Km = 37), an approximate human equivalent dose (HED) can be estimated from the mouse IP dose:

• Mouse dose: 5 mg/kg
• BSA-scaled HED: 5 mg/kg x (3/37) = approximately 0.41 mg/kg
• For a 70 kg human: approximately 28.5 mg per dose

This calculation is provided purely for academic context. It does not account for differences in bioavailability between IP injection in mice and any route of administration in humans, species-specific differences in MOTS-c metabolism and clearance, pharmacokinetic differences that could substantially alter effective dose ranges, or the possibility that optimal human dosing may bear no predictable relationship to mouse dosing.

Pharmacokinetic Considerations#

The pharmacokinetics of exogenous MOTS-c have not been well characterized even in animal models. Key gaps include:

• Plasma half-life: Not determined in published studies. As a 16-amino acid peptide without stabilizing modifications, MOTS-c is expected to have a short circulating half-life due to proteolytic degradation, though the exact duration is unknown.
• Bioavailability: Only IP injection data exist. Absolute bioavailability by any route has not been reported.
• Distribution: MOTS-c has been shown to translocate to the nucleus in cell studies, suggesting intracellular uptake, but tissue distribution after systemic administration has not been comprehensively mapped.
• Metabolism: The metabolic fate of exogenous MOTS-c has not been characterized. The two methionine residues are vulnerable to oxidation, and general proteolytic degradation is expected.
• Elimination: Excretion routes and clearance rates have not been published.

Endogenous MOTS-c has been detected in human plasma at measurable levels, and circulating concentrations decline with age. However, endogenous levels and the pharmacokinetics of exogenous administration are distinct considerations.

Storage and Handling#

While specific stability data for MOTS-c have not been extensively published, standard peptide handling guidelines should be followed for research purposes:

• Lyophilized peptide should be stored at -20 degrees C or lower
• Reconstituted solutions should be stored at 2-8 degrees C and used within a timeframe consistent with the specific formulation
• Avoid repeated freeze-thaw cycles
• Protect from light and oxidizing conditions, as the two methionine residues in MOTS-c are susceptible to oxidative modification
• Use sterile technique for reconstitution and handling

Critical Limitations#

The dosing information presented here is derived entirely from preclinical mouse studies. The following critical limitations apply:

• No human dose-finding studies have been conducted
• The 5 mg/kg IP mouse dose is a research tool, not a translational recommendation
• Intraperitoneal injection pharmacokinetics do not translate directly to subcutaneous or other human-relevant routes
• Individual variation in endogenous MOTS-c levels, metabolic status, and drug metabolism could substantially affect dosing requirements
• The relationship between MOTS-c dose and AMPK activation in human tissues has not been established
• Duration of treatment, cycling protocols, and long-term dosing strategies have not been investigated
• Without human pharmacokinetic data, any dose calculation is speculative

Related Reading#

• MOTS-c overview and research guide
• MOTS-c side effects profile
• MOTS-c research evidence